Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s Venture Fund Invests in Cellarity
October 6, 2022
- Shionogi, UN Agency Tie Up for Generic Distribution of COVID Pill in Low-Middle-Income Nations
October 5, 2022
- Astellas/Pantherna Expand mRNA-Based Regenerative Medicine Collab to Add New Target Organ
October 5, 2022
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
- Takeda to Discontinue Natpar/Natpara Production at End of 2024
October 5, 2022
- Sumitomo Rolls Out Hand Rehabilitation System in Japan as 1st Frontier Business Product
October 4, 2022
- Idorsia’s Insomnia Med Meets PIII Goal in Japan, Filing Planned for H1 2023
October 4, 2022
- Shionogi to End Sale of Aimix, Sumitomo to Continue
October 4, 2022
- Taiho Gets US Nod for Bile Duct Cancer Drug Futibatinib
October 4, 2022
- Sun Pharma Taps Haruko Yamabe as Japan Chief
October 4, 2022
- Novartis Homes in on 5 Therapy Areas and 4 Markets, Eyes Top 3 Multinational Rank in Japan: CEO
October 4, 2022
- Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
October 3, 2022
- Novartis Ordered to Pay US$177.8 Million to Daiichi Sankyo over Patent Row
October 3, 2022
- Rohto Begins PIIb Dry Eye Study for JAK Drug Delgocitinib in Japan
October 3, 2022
- EMA Accepts Astellas’ Hot Flash Drug for Review
October 3, 2022
- Sanofi Seeks Japan Nod for Once-Weekly Hemophilia Med
October 3, 2022
- Ferring Japan CEO Confident of Growth in Fertility Drugs Spurred by Rising Demand on Health Coverage
September 30, 2022
- Lilly Japan, DeNA Partner Up to Recruit Trial Participants with Collected Genetic Data
September 30, 2022
- US QIDP Status Awarded to Meropenem Combo Med for Carbapenem-Resistant Bacteria Infections: Kitasato/Sumitomo
September 30, 2022
- Chugai Files Perjeta/Herceptin Subcutaneous Combo in Japan
September 30, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…